| Code | CSB-RA001260MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to LAE-102, targeting ACVR2A (Activin Receptor Type 2A), a transmembrane serine/threonine kinase receptor that plays a critical role in TGF-β superfamily signaling. ACVR2A mediates cellular responses to activins, myostatin, and related ligands, regulating diverse biological processes including muscle growth, bone metabolism, and cellular differentiation. Dysregulation of ACVR2A signaling has been implicated in multiple pathological conditions, including muscle wasting disorders, fibrodysplasia ossificans progressiva, and certain cancers where aberrant activin signaling contributes to tumor progression and metastasis.
LAE-102 has been utilized in research investigating ACVR2A-mediated signaling pathways and their therapeutic potential in muscle disorders and metabolic diseases. This biosimilar antibody provides researchers with a reliable tool for exploring ACVR2A function in various experimental contexts, including studies of receptor localization, protein-protein interactions, and pathway modulation. It supports investigations into the therapeutic targeting of activin-myostatin signaling for conditions involving muscle atrophy, metabolic dysfunction, and bone homeostasis.
There are currently no reviews for this product.